After job cuts, Raleigh drugmaker considers selling lead product


Months after slashing its U.S. commercial workforce, a Raleigh pharmaceutical company may be looking to offload its lead commercial product as it faces scrutiny from a lender.

Previous Breaking: Black Business Investment Fund to get Truist grant. Here's what it's for.
Next Fiserv HQ moving to downtown Milwaukee, adding 250 jobs